AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02983136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialogue and inter-professional learning
Description: The middle and front-line leaders of the study OR will participate in an intervention based on an iKT model. Components of the intervention will include:~* Two workshops, consisting of educational sessions covering the state of the art regarding person-centeredness, prevention of infections, leadership, and implementation. The educational component and results of pre-studies will work as frameworks for the dialogues between the front-line leaders and the research group. In dialogues the participants will be given the opportunity to reflect on barriers to and enablers of change; and~* The participants will be supported in creating an action plan aimed at facilitating the anaesthesia providers' change of practice.
Study NCT01781520 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC-CIK Treatment
Description: The DC-CIK cells were infused on days 15, 17, and 19 of 21-day cycles.
Study NCT01781520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK Treatment
Description: The DC-CIK cells were infused on days 15, 17, and 19 of 21-day cycles.
Study NCT01781520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S1
Description: The dose of S-1 is determined according to the body surface area as follows: \<1.25 m2, 40 mg; 1.25-\<1.5 m2, 50 mg; and >1.5 m2, 60 mg, given twice daily after meals for 14 days followed by a 7-day rest. Cycles is repeated every 21 days. Treatment is continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
Study NCT00370890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (gemcitabine and cisplatin)
Description: Gemcitabine 1000 mg/m2 in 250 ml NS over 30 mins IV on Day 1 and 8 Cisplatin 40 mg/m2 in 1L NS over 2 h IV on Day 1 and 8 Cycle repeated every 3 weeks for total of 6 cycles
Study NCT01606293 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Completion of online surveys taking approximately 15 - 20 minutes.
Study NCT01178736 — intervention group
Intervention type: PROCEDURE
Intervention: Breast Cancer Screening and Diagnosis
Description: Clinical Breast Examination and Sonography followed by Fine needle aspiration biopsy (FNAB) of screen positive cases.
Study NCT01178736 — intervention group
Intervention type: PROCEDURE
Intervention: Cervical Cancer Screening and Diagnosis
Description: Visual Inspection with Acetic acid, PAP smear or Human Papilloma Virus DNA testing followed by Cryotherapy of screen positive cases.
Study NCT01178736 — intervention group
Intervention type: PROCEDURE
Intervention: Ovarian Cancer Screening and Diagnosis
Description: Transvaginal sonogram and clinical evaluation in post menopausal women with symptoms suggestive of ovarian cancer.
Study NCT02187497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium dose of BIBR 277
Study NCT02187497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of BIBR 277
Study NCT01128556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepreve
Description: Bepreve (bepotastine besilate ophthalmic solution 1.5%) one drop in each eye twice daily
Study NCT01128556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Refresh Tears
Description: Refresh Tears one drop to each eye twice daily for 7 days after the conclusion of Bepreve treatment
Study NCT01100671 — intervention group
Intervention type: OTHER
Intervention: Cross section study
Description: This is not intervention study. The purpose of the study is to examine the relationship of vascular inflammation assessed by 18FDG-PET and MDCT at the cross section setting
Study NCT02201641 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cone Beam computed tomography (Morita Accuitomo)
Description: CBCT scans are taken to assess the efficacy of this method in detecting the presence of early peri-radicular lesions.
Study NCT02201641 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Periapical radiographs
Description: Periapical radiographs are taken as a control to detect the presence of early peri-radicular lesions.
Study NCT02201641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: calcium silicate cement (Biodentine™)
Description: calcium silicate cement (Biodentine™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.
Study NCT02201641 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: glass ionomer cement ( Fuji IX™)
Description: glass ionomer cement ( Fuji IX™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulp.
Study NCT03158896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCTC-0010 Dose Escalation
Description: Cohort 1: 2.0 × 106 cells per kilogram (cells/kg) body weight, given on day 0 and on day 7 in Participants having de novo High Risk Acute or Steroid Refractory Acute Graft Versus Host Disease (HR/SR aGvHD)~Cohort 2: 10 × 106 cells/kg of body weight, given on day 0 and on day 7 in Participants having de novo HR/SR aGvHD
Study NCT04404205 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Postural stability measurements by Biodex Balance System
Description: Postural stability measurements will be done by Biodex Balance System. Three preprogrammed main tests will be applied. Postural stability, fall index, sensory integration will be calculated. All tests will be done in four conditions; implant off(1), implant on(2), implant on music on(3), and implant off again(4).
Study NCT02563171 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non surgical periodontal treatment
Description: 1. SRP under local anaesthesia, in a total of 2-3 clinical visits.~2. Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
Study NCT02563171 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gingival crevicular fluid collection
Description: GCF collection with filter paper (Periopaper) using the intracrevicular method.
Study NCT06184386 — intervention group
Intervention type: OTHER
Intervention: NIDCAPARENTALIM
Description: PARENTALIM practice that strengthens the NIDCAP. It is proposed in a routine way in the NICU since 2019. PARENTALIM supports and monitors parental implication in nursing care. It is led by a speach language therapist specialized in early feeding development who proposes 5 individualized interviews and uses an educational booklet on eating development care with a lot of illustrations and few words.
Study NCT01781520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: The dose of S-1 is determined according to the body surface area as follows: \<1.25 m2, 40 mg; 1.25-\<1.5 m2, 50 mg; and >1.5 m2, 60 mg, given twice daily after meals for 14 days followed by a 7-day rest. Cycles is repeated every 21 days. Treatment is continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
Study NCT01781520 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best supportive care
Description: Best supportive care
Study NCT01047930 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Each 3-day experimental period will include one of the following conditions:~1. Morning exercise - subject will exercise on each of the three mornings in the sleep laboratory, starting 30 minutes after their habitual rise-time;~2. Evening exercise - subject will start exercise 4 hours before their habitual bedtime on each of the three evenings;~3. No exercise - subject will watch television or read and they will be required to remain sedentary.
Study NCT02606175 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Taking questionnaires and tests
Description: At predefined timepoints:~* 2 tests for health literacy: New Vital Sign-Dutch version (NVS-D) and Functional, Communicative and Critical Health Literacy (FCCHL)~* 1 test for medication adherence: BAASIS~* 1 questionnaire about demographic factors (weight, income, sex, age, financial situation,...)~* 1 test about medication knowledge
Study NCT04982874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg
Description: Administered with 240 mL of water
Study NCT04982874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lasix® 40 mg Tablet
Description: Administered with 240 mL of water
Study NCT00925899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 20 mg melatonin orally every evening about 1 hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of melatonin followed by one week of placebo, or the other way around), the participant may receive melatonin for 6 weeks.
Study NCT00925899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet orally every evening about one hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of placebo followed by one week of melatonin, or the other way around), the participant may receive melatonin for 6 weeks.
Study NCT06184386 — intervention group
Intervention type: BEHAVIORAL
Intervention: SOFS
Description: SOFS is a behavioral practice of orofacial stimulations. Il has been mainly carried out by nurses or a speach language therapist specialized in early feeding development. SOFS has been applied through routine protocol in the NICU until 2018.
Study NCT01389388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: All the patients who have signed the informed consent will after they have had performed a MCT and possibly SCC with an IVUS, will be give Rosuvastatinuntill their LDL level has reached 1.6-1.8 mmol/l. The objective is that all the participants should have reached 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
Study NCT00295607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: immunosuppression
Study NCT00295607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: immunosuppression
Study NCT00295607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: steroids, monoclonal anti-IL2R antibody
Description: immunosuppression
Study NCT03730610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Subjects are required to exercise four times a week during six months. Exercise training consists of endurance training, resistance training and high-intensity interval training adjusted to subject's fitness level.
Study NCT01352286 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous Genetically modified T cells
Description: Patients will undergo myeloma restaging at days +42, +100, 6 months, 9 months and 1 year post infusion. At this point, in accordance with FDA Guidelines, all patients will enter long term follow up (LTFU) and be followed biannually for monitoring for gene transfer delayed adverse events until year 5 post infusion. From year 5, all patients will require annual LTFU visits for monitoring for delayed adverse events until year 15 after receiving the genetically modified T cells.~Patients whose disease progresses prior to year 1 will enter LTFU at time of progression; however these patients will be seen quarterly from progression until year 1 post infusion and then follow the LTFU schedule mentioned above.
Study NCT01771874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: 125 mg per os, single dose
Study NCT01771874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion will be administered in a dose of 150mg (Wellbutrin XR) once-daily in the morning for three days followed by 300mg (2x150mg) for 4 days before the test day. On the test day, a final dose of 300mg will administered 2 hours before the administration of MDMA 125 mg or placebo.
Study NCT01771874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: per os
Study NCT01079325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-509
Description: SB-509 60 mg, 3 treatments, and 5 months treatment period
Study NCT01079325 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT02847169 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: filcon IV1 toric lens
Description: toric contact lens
Study NCT02847169 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ocufilcon D toric lens
Description: toric contact lens
Study NCT03670849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LapAR
Description: LapAR system will map (transform) the live LUS image in the reference frame of the laparoscopic camera, and fuse it with the live laparoscopic video in real time. For thermal ablations that involve a needle, we also track the needle and overlay its path on the AR view.
Study NCT01178736 — intervention group
Intervention type: PROCEDURE
Intervention: Endometrial Cancer Screening and Diagnosis
Description: Transvaginal sonographic assessment of the endometrial stripe in post menopausal women with abnormal bleeding.
Study NCT00994903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40mg orally, given 3-7 days pre-op and continued till 14 days post-op
Study NCT00994903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Inert calcium lactate) tablets 3-7 days pre-op to 14 days post-op (as per experimental arm)
Study NCT04396821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST001
Description: TST001 is a humanized IgG1 monoclonal antibody.
Study NCT04396821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: Nivolumab is one of the PD-1 checkpoint inhibitors, and has proved clinical benefit for multiple late-stage malignancies
Study NCT01061411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin
Description: Given SC
Study NCT01061411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01061411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study NCT04396821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: mFOLFOX6 is a combination chemotherapy regimen including the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.
Study NCT04396821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy medication
Study NCT03366038 — intervention group
Intervention type: PROCEDURE
Intervention: Shark Mouth Modified Pancreaticojejunostomy
Description: The remnant of jejunum is closed by continuous suture. The transverse incision is made on the posterior wall of the jejunum (5 centimeters distal to remnant）, which starts at 0.2 centimeter to the mesenteric border and should never exceed the anti-mesenteric border . In case of large pancreas remnant, a longitudinal jejunum incision will be done at anterior part of anastomosis.~The posterior part of anastomosis is two layers of intermittent suture, including seromuscular suture layer and full thickness suture layer. The anterior part of anastomosis is a single layer full thickness suture. At last, the seromuscular layer of the proximal jejunum is sutured with the anterior pancreatic capsule to cover the anterior part of anastomosis.
Study NCT00517335 — intervention group
Intervention type: PROCEDURE
Intervention: Functional magnetic resonance imaging (fMRI) scan
Description: Healthy control women, recovered bulimia women, and also recovered anorexia women will complete specific tasks in an fMRI scanner that will take up to 60 minutes.
Study NCT04396821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: Chemotherapy medication
Study NCT01647646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide
Description: Using Symbicort and Seretide for asthma control measurements Compared with efficacy and safety
Study NCT02691221 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relief Link Application Daily Tasks
Description: Participants will complete daily mood tracking and completion of a minimum of one stress management activity per day. Relaxation exercises to choose from on the current version of RL are audio files (i.e., no visuals), and consist of: Guided Meditation, Energizing Breath, Guided Visualization for Relaxation, Progressive Relaxation, Mindfulness Meditation Body Scan, and Mindfulness of Breathing.
Study NCT03560635 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Maintenance (Control vs. Reverse Diet)
Description: Participants in both groups will receive a 12-week comprehensive, individually delivered behavioral weight loss maintenance intervention, adapted from the Diabetes Prevention Program (DPP) Post-CORE program. This program focuses on utilization of tools and strategies to maintain a healthy lifestyle and prevent weight regain, and is therefore most appropriate for the weight-reduced population we will enroll. While the DPP Post-CORE program includes 15 sessions delivered over 15-months, we will deliver sessions #1-12 and 15 over a 12-week period. Content for sessions 13 and 14 from the DPP Post-CORE curriculum focus specifically on Type 2 Diabetes Mellitus and Heart Disease. The informational handouts will be provided to participants, but not specifically covered in weekly meetings. Groups will differ only in specific caloric prescriptions (described in the Arms section).
Study NCT03560635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Maintenance (Control vs. Reverse Diet)
Description: Participants in both groups will receive a 12-week comprehensive, individually delivered behavioral weight loss maintenance intervention, adapted from the Diabetes Prevention Program (DPP) Post-CORE program. This program focuses on utilization of tools and strategies to maintain a healthy lifestyle and prevent weight regain, and is therefore most appropriate for the weight-reduced population we will enroll. While the DPP Post-CORE program includes 15 sessions delivered over 15-months, we will deliver sessions #1-12 and 15 over a 12-week period. Content for sessions 13 and 14 from the DPP Post-CORE curriculum focus specifically on Type 2 Diabetes Mellitus and Heart Disease. The informational handouts will be provided to participants, but not specifically covered in weekly meetings. Groups will differ only in specific caloric prescriptions (described in the Arms section).
Study NCT02887859 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Acellular Vessel (HAV)
Description: Patients will be implanted with a Human Acellular Vessel (HAV) as a femoro-popliteal bypass conduit using standard vascular surgical techniques
Study NCT03496129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized feedback
Description: Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).
Study NCT03496129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized feedback and text messages
Description: Experimental: Personalized feedback and text messages~Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions.
Study NCT03496129 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Only
Description: Active Comparator: Information Only~Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message.
Study NCT04046341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Well!
Description: The intervention comprehensively addresses poor sleep health behaviors (e.g., use of electronics at bedtime; inconsistent and variable sleep schedules; lack of a bedtime routine) as well as insomnia (difficulty falling and staying asleep; the need for caregiver presence at bedtime) and insufficient sleep in toddlers and preschoolers. Interventionists will use strategies to engage with and empower families, such as motivational interviewing and collaborative problem-solving. Session content will be reinforced via phone calls from interventionists. Families will receive intervention session appointment reminders and information about intervention content (e.g., reminders to follow a bedtime routine) via text message.
Study NCT02322268 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cosmos Caudatus
Description: 15g of Cosmos caudatus consumed with lunch or dinner
Study NCT04328233 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted Eating
Description: Participants will reduce the amount of time they eat to 10 hours per day over a 12-week monitored intervention followed by a 12-week self-directed intervention and will log their dietary intake using a smartphone application (mCC app). The participants will select a 10-h eating window that best suits their lifestyle. All food/beverages except water must be consumed within the time-interval. No further dietary restrictions will be applied. The participants will be provided with behavioral nutritional counseling by a dietician.